Gliomas with mutations in isocitrate dehydrogenase 1 or 2 ("IDHmut") are associated with increased risk of seizures, and IDHmut gliomas are nearly always found in conjunction with TP53 and ATRX mutations in astrocytomas, or TERT promoter mutations and 1p/19q codeletion in oligodendrogliomas. IDHmut gliomas are also less aggressive than their IDHwt counterparts, but still usually recur after treatment and are ultimately fatal; breakthrough seizures are often a harbinger of such recurrences. Here, we report an extremely unusual case where a low-grade glioma only had IDHmut and did not recur or cause breakthrough seizures until 22 years after original diagnosis, without a progression in grade. Yet, seizures manifested at both the secondary presentation and recurrence. This case raises questions about the nature of IDHmut and its natural course when secondary TP53/ATRX or TERT/1p/19q alterations do not develop.

Case Report

A 37-year-old female, with no prior medical history, suffered a first-time bilateral tonic-clonic seizure. Imaging at an outside institution revealed a right-sided lesion involving her primary motor strip (images not available). Because of this sensitive location, surgical management was limited to a biopsy, but this biopsy did not yield a firm diagnosis and was deemed non-diagnostic (outside pathology not available). Soon after that biopsy, the patient had her first focal seizure, characterized by clonic movements of the left arm and face. She was initially started on phenobarbital, and carbamazepine was subsequently added due to continued focal motor seizures of the left hand. Later that year, the patient underwent a craniotomy and a second biopsy, again at an outside institution, which generated a pathologic diagnosis of diffuse astrocytoma, WHO grade 2. Adjuvant therapy included 30 fractions of radiation, but no chemotherapy. She was weaned off phenobarbital, continued carbamazepine monotherapy, and remained seizure-free on that regimen for 22 years, with stable MRIs during that entire time.

Twenty-two years after her first seizure, the patient (now 59) experienced a focal seizure that was characterized by clonic movements of the left arm and face lasting approximately 15 minutes. An MRI showed an ill-defined lesion in the right frontal perirolandic area with equivocal contrast enhancement (Figure 1). The patient continued to experience focal seizures multiple times a day while still taking carbamazepine, so she was gradually switched to levetiracetam 1000 mg BID. During that transition, she experienced a prolonged focal motor seizure, involving her left arm and face that required hospitalization and intravenous medication to stop. Thus, she was switched back to carbamazepine, but continued to experience one or two focal motor seizures a day. She was then started on clonazepam 1 mg bid, gradually transitioned to clobazam, and her seizures stopped. She has remained seizure-free ever since.

After medication adjustments stabilized her seizures, the patient underwent another biopsy to determine whether the astrocytoma had recurred and progressed.

Pathology and Molecular Diagnostics

The newest biopsy from the right motor strip, 22 years after initial disease presentation, showed mildly hypercellular gray matter with extensive vascular hyalinization, the latter attributable to the remote history of radiotherapy (Figure 2A). Although no obvious glioma cells were identified, immunohistochemistry (IHC) for the canonical isocitrate dehydrogenase 1 (IDH1) R132H mutation revealed unequivocally positive cells with long, ramified processes (Figure 2B and C). Neither p53 nor ATRX IHC showed abnormal accumulation or loss, respectively (not shown). Ki67 IHC showed an overall low Ki67 proliferation index, with only a few scattered cells that were immunopositive (Figure 2D). No necrosis, mitoses, or microvascular proliferation were identified.

Next-generation sequencing of the newest biopsy confirmed the IDH1 R132H mutation with a 7% variant allelic fraction, as well as positive MGMT promoter methylation. No other molecular alterations were detected, including no mutations in...
ATRX, TP53, or TERT promoter, and no copy number alterations on chromosomal microarray.

Discussion

Molecular diagnostics has revolutionized the workup and classification of central nervous system tumors, allowing for more accuracy than by evaluation of histological findings alone. The original papers describing IDH\textsuperscript{mut} gliomas were published in 2008 and 2009.\textsuperscript{1,2} Now, the classification of adult-type diffuse gliomas is based on the presence or absence of IDH\textsuperscript{mut} (and 1p/19q codeletion).\textsuperscript{3} IDH\textsuperscript{mut}, TERT\textsuperscript{wt}, 1p/19q-intact gliomas are astrocytomas, and the vast majority of IDH\textsuperscript{mut} astrocytomas contain mutations in TP53 and/or ATRX.\textsuperscript{4,5} In our analysis of 240 IDH\textsuperscript{mut}, TERT\textsuperscript{wt}, 1p/19q-intact astrocytomas in The Cancer Genome Atlas (TCGA) via GlioVis,\textsuperscript{6} only four (1.7%) were wild-type for both TP53 and ATRX. All four were histologically grade 2, all occurred in 20- to 30-year-old patients (three of whom were female), and all four patients had survived at least 17 months after diagnosis, with no recorded deaths in the database.

IDH\textsuperscript{mut} appears to be the first alteration to occur in IDH\textsuperscript{mut} astrocytomas, with TP53 and/or ATRX arising later.\textsuperscript{7,8} In the current case, the initial tumor was diagnosed by microscopy as a grade 2 astrocytoma, about 10 years before the discovery of IDH\textsuperscript{mut} in gliomas. Although the original tumor tissue was not available, it seems reasonable to assume that IDH\textsuperscript{mut} was present at that time. While IDH\textsuperscript{mut} gliomas are less aggressive compared to IDH\textsuperscript{wt} glioblastomas, IDH\textsuperscript{mut} gliomas are ultimately fatal in the overwhelming majority of cases. Even in the least aggressive subtype—IDH\textsuperscript{mut}, 1p/19q-codeleted oligodendrogliomas—survival beyond 15 years is uncommon. In the current case, after 22 years, the recurrent tumor cells were difficult to detect by microscopy, and by molecular testing, those cells only had IDH\textsuperscript{mut}. This suggests that IDH\textsuperscript{mut} by itself acts in a relatively indolent manner, and that most cases coming to clinical attention do so because they acquire additional TP53 and ATRX alterations (or TERT promoter mutations and 1p/19q codeletion), thereby accelerating tumor proliferation and evolution. Indeed, the long cell processes highlighted by IDH1 R132H IHC (Figure 2C) imply fundamentally more mature tumor cells in this case than are usually encountered in IDH\textsuperscript{mut} astrocytomas. This case also invites speculation as to how often IDH\textsuperscript{mut} occurs in the brain in isolation, and whether most instances might never come to clinical attention if it remains an isolated mutation, especially if it arises in areas less sensitive than the primary motor strip.

This patient’s original tumor, and the first recurrence 22 years later, both manifested as seizures. As the tumor was located in the primary motor strip, those seizures were quite apparent, even though the actual tumor burden (as indicated by variant allelic fraction) was low compared to what is typical for most glioma patients. Our prior work, and that of others, consistently showed that IDH\textsuperscript{mut} gliomas are more likely to present as seizures than IDH\textsuperscript{wt} glioblastomas, even though the latter are more aggressive.\textsuperscript{9–12} Specifically, the D-2-hydroxyglutarate product of IDH\textsuperscript{mut} is secreted by glioma cells and is sufficient to trigger synchronized network bursts in cultured neurons.\textsuperscript{9,13} The association between breakthrough seizures and glioma recurrence is also well known,\textsuperscript{14} although such prolonged intervals between original diagnosis and recurrence are highly unusual, even in IDH\textsuperscript{mut} gliomas.
In summary, this case highlights an extremely rare instance of isolated IDH\textsuperscript{mut} in glioma, with a similarly rare extended patient survival. This also illustrates the fidelity of breakthrough seizures as a marker of glioma recurrence, even in such a prolonged disease course.

**Keywords**

IDH1 mutation | recurrence | seizure | survival

**Funding**

This work was supported in part by National Institutes of Health grant R01NS102669, R01NS117104, and R01NS18039 (C.H.) as well as by the Northwestern SPORE in Brain Cancer P50CA221747 and the Lou and Jean Malnati Brain Tumor Institute.

**Acknowledgments**

Not applicable.

**Conflict of interest statement.** The authors declare that they have no competing interests.

**Authorship statement.** M.D., J.W.T., L.J., and C.H. prepared the data, text, and figures. M.D., MT, J.W.T., and C.H. edited the manuscript.

**Ethics approval and consent to participate.** Not applicable.

**Consent for publication.** Not applicable.

**References**

1. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. *Science*. 2008;321(5897):1807–1812.
2. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. *N Engl J Med*. 2009;360(8):765–773.
3. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. *Neuro Oncol*. 2021;23(8):1231–1251.
4. Brat DJ, Verhaak RG, Aldape KD, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. *N Engl J Med*. 2015;372(26):2481–2498.
5. Suzuki H, Aoki K, Chiba K, et al. Mutational landscape and clonal architecture in grade II and III gliomas. *Nat Genet*. 2015;47(5):458–468.
6. Bowman RL, Wang Q, Carro A, Verhaak RG, Squatrito M. GlioVis data portal for visualization and analysis of brain tumor expression datasets. *Neuro Oncol*. 2017;19(1):139–141.
7. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. *Am J Pathol*. 2009;174(4):1149–1153.
8. Lai A, Kharbanda S, Pope WB, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. *J Clin Oncol*. 2011;29(34):4482–4490.
9. Chen H, Judkins J, Thomas C, et al. Mutant IDH1 and seizures in patients with glioma. *Neurology*. 2017;88(19):1805–1813.
10. Feyissa AM, Worrell GA, Tatum WO, et al. Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control. *Seizure*. 2019;69:283–289.
11. Phan K, Ng W, Lu VM, et al. Association between IDH1 and IDH2 mutations and preoperative seizures in patients with low-grade versus high-grade glioma: a systematic review and meta-analysis. *World Neurosurg*. 2018;111:e539–e545.
12. Stockhammer F, Misich M, Helms JU, et al. IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. *Seizure*. 2012;21(3):194–197.
13. Linninger A, Hartung GA, Liu BP, et al. Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system. *Neuro Oncol*. 2018;20(9):1197–1206.
14. Kerkhof M, Vecht CJ. Seizure characteristics and prognostic factors of gliomas. *Epilepsia*. 2013;54(Suppl 9):12–17.